StockNews.com Initiates Coverage on Check-Cap (NASDAQ:CHEK)

StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note released on Saturday. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Price Performance

Shares of CHEK opened at $0.87 on Friday. Check-Cap has a 12-month low of $0.80 and a 12-month high of $3.85. The stock has a market capitalization of $5.07 million, a P/E ratio of -0.28 and a beta of 0.39. The firm’s 50 day moving average is $1.45 and its 200-day moving average is $1.86.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.